Novartis is set to acquire Gyroscope Therapeutics in a deal that could be worth up to $1.5 billion, according to press releases from both companies.
The deal includes an upfront payment of $800 million, while up to $700 million could be included if certain milestones are met.
The centerpiece of the deal is GT005, Gyroscope’s investigational gene therapy for geographic atrophy (GA) secondary to age-related macular degeneration. The treatment recently showed potential to regulate the complement pathway of GA in the phase 1/2 FOCUS trial.
“With our own pioneering research (Read more...)